Ii-Key/前列腺特异性抗原CD4^+T细胞表位肽融合疫苗的制备及对PBMC的增殖影响的实验研究  

Ii-Key/prostate specific antigen CD4^+T cell epitope peptide hybrid vaccine induce anti-prostate cancer immunoresponse in vitro

作　　者：何建川[1] 邵阳[2] 

机构地区：[1]川北医学院基础医学院,南充637000 [2]川北医学院影像研究所,南充637000

出　　处：《免疫学杂志》2013年第10期859-862,共4页Immunological Journal

摘　　要：目的预测并鉴定前列腺癌特异性抗原CD4+T细胞表位,并构建Ii-Key/前列腺癌特异性抗原CD4+T细胞表位肽(IiKey/PSA)疫苗的抗肿瘤效应。方法采用syfpeithi表位预测软件进行表位预测,采用酶联免疫斑点检测、淋巴细胞增殖实验对表位活化淋巴细胞的能力进行检测。结果我们预测的5条表位肽中PSA154是前列腺特异性抗原CD4+T细胞的优势表位,Ii-Key/PSA154疫苗诱导淋巴细胞活化的能力强于PSA154表位肽。结论 Ii-Key/PSA154在体外实验中显示了较强的免疫效应,可作为多肽疫苗用于表达前列腺癌特异性抗原的前列腺癌的免疫治疗。This study was designed to predict and identify prostate cancer-specific antigen CD4＋T cell epitopes for building Ii-Key/prostate cancer specific antigen CD4＋T cell epitope peptides（Ii-Key/PSA）,and to evaluate the anti-tumor effect of the vaccine in vitro.Syfpeithi epitope prediction software was employed to predict the epitope,while ELISPOT assay and lymphocyte proliferation assay were used to determine the ability of epitope to activate lymphocytes.Results showed that total of 5 epitopes were predicted,in which PSA154 is a superior epitope.And Ii-Key/PSA154 vaccine could induce stronger immunoresponses than PSA154 epitope peptide did.In conclusion,Ii-Key/PSA154 could use as a vaccine for prostate cancer immunotherapy.

关 键 词：前列腺癌特异性抗原 抗原表位 T淋巴细胞 肿瘤免疫治疗 

分 类 号：R392.9[医药卫生—免疫学]